- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Non-small cell lung cancer
- Meeting Date: November 2022
- Public Summary Document (PSD) November 2022 PBAC Meeting - (PDF 1.4KB)
- Public Summary Document (PSD) November 2022 PBAC Meeting - (Word 858KB)
Mobocertinib – November 2022
Mobocertinib: Capsule 40 mg; Exkivity®
Last updated
17 March 2023